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THE REBOUND PHENOMENON IN ACUTE RHEUMATIC FEVER
II. TREATMENT AND PREVENTIONt
The post-therapeutic rebound phenomenon in acute rheumatic fever may
include clinical features or may consist only of abnormalities in laboratory
tests. A survey' of these events has shown that "laboratory" rebounds were
invariably benign, did not correlate with preceding therapy or with cardiac
status, and subsided spontaneously. In contrast, the "clinical" rebounds
were sometimes worse than the manifestations of the original attack, had an
increased incidence with increasing severity of heart disease, occurred more
frequently in patients who received steroids than in those who did not, and
carried the threat of additional cardiac damage.
The prevention of clinical rebounds has been attempted by several thera-
peutic designs. Most designs relate to the length, dosage, and supplements
of steroid therapy, and the use of salicylates alone is seldom considered.
In one plan'0'18""' steroid treatment is continued for a long time with an
extended period of gradual reduction before it is stopped. In another" the
steroids are given at high dosage but only for one or two weeks. A third
approach has added salicylates to the steroids and continued salicylate treat-
ment after the steroids are discontinued.8"- 28 Within their basic structure,
these three therapeutic plans have numerous minor variations. No studies
have compared the three programs, and their relative effectiveness is
uncertain.
Other uncertainties and controversies surround the management of
rebound phenomena. At one extreme is the belief" that suppressive therapy
should be resumed whenever a rebound occurs, regardless of its clinical or
laboratory manifestations. At the other extreme is the implication' that
additional treatment is often undesirable because further suppression of the
rheumatic inflammation may result in recurrent rebounds when the treat-
* Resident Physician, Irvington House.
** Medical Director, Irvington House; Assistant Professor of Medicine, New York
University School of Medicine.
t Supported in part by Fellowship from the New York State Department of Health.
Received for publication 4 June 1960.
279YALE JOURNAL OF BIOLOGY AND MEDICINE
ment is stopped. Between these extremes are other treatment programs
based upon specific aspects of the clinical situation.
In an attempt to clarify some of these problems, the present study has
analyzed the management and sequelae of rebounds and methods for
preventing rebounds.
CLINICAL MATERIAL AND METHODS
The criteria for rheumatic activity, laboratory rebounds and clinical rebounds, and
the classification of the patients' clinical status were described in detail previously.'
The basic population of the present report consists of the same 265 children and
adolescents with acute rheumatic fever who were studied previously. They represented
all the patients whose attacks fulfilled the modified Jones diagnostic criteriae and who
were admitted to Irvington House consecutively from 1 July 1956 to 31 August 1958.
In 96 patients of this group laboratory rebounds occurred and their sequelae have been
described here. In 49 patients clinical rebounds occurred. To obtain more clinical
rebounds for this study, an additional 15 patients were added to this original group.
The extra 15 patients represented all the clinical rebounds encountered in the 150
consecutive patients with unequivocal rheumatic fever admitted to Irvington House
from 1 September 1958 to 30 August 1959. Thus, the 64 patients whose clinical rebounds
have been analyzed below in Figures 4 to 6 and Tables 1 to 3 comprise all the instances
of this event in 415 consecutive cases of rheumatic fever seen in a 3-year period ending
30 August 1959.
The prevention of post-steroid clinical rebounds was attempted, whenever possible,
in all patients admitted to Irvington House after November 1958. The previous study
of rebounds' had been completed at that time, and its conclusions suggested that the
incidence of post-steroid clinical rebounds might be reduced by the concurrent use of
salicylates. Accordingly, in patients who arrived at Irvington House while receiving
steroids alone, salicylates were usually added to the program when the reduction and
tapering of steroids began, and salicylates were continued after the steroids were stopped.
The success of this form of "overlap" treatment in preventing clinical rebounds has
been tabulated here (Table 4) and compared against results obtained with another
form of combined therapy in which steroids and salicylates are begun simultaneously.
Although these different groups of patients were studied consecutively rather than
concomitantly, they were quite similar in regard to the other major parameters of the
rheumatic attacks and differed significantly only in the type of anti-inflammatory
therapy given in the late stages of their treatment.
RESULTS
Sequelae and management of laboratory rebounds
None of the original laboratory rebounds was treated; an additional
(secondary) laboratory rebound occurred spontaneously after subsidence of
the initial abnormalities in 19 of the 96 patients. All the secondary labora-
tory rebounds also subsided spontaneously, and had no apparent effect on
the clinical status. The effects of anti-inflammatory treatment in a situation
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resembling a laboratory rebound are shown in Figure 1. This patient's ini-
tial clinical features were arthritis without valvular involvement. He was
treated with salicylates and experienced a clinical rebound when the therapy
was stopped. The clinical features then subsided spontaneously, but the
acute phase reactants were still abnormally elevated. At this time, while the
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FIG. 1. Occurrence of a clinical rebound after salicylate therapy given at time of
abnormalities only in laboratory tests. The first attack of rheumatic fever in this
8-year-old boy produced polyarthritis without carditis and responded well to salicylate
treatment. When the latter was discontinued after three weeks, arthritis recurred.
It had subsided spontaneously but acute phase reactants were still abnormal when the
patient received two weeks of aspirin for investigative purposes. Cessation of the
aspirin was followed by a clinical rebound with arthritis, fever, and laboratory
abnormalities. (See text.)
patient had only laboratory abnormalities, a course of aspirin therapy was
given as part of a study of the effect of salicylate upon serum transaminase?'
When the latter course of aspirin was stopped, the patient then had another
clinical rebound. This unexpected result confirms a previous observations
that the use of suppressive treatment for laboratory abnormalities may be
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FIG. 2. Appearance of nezv cardiac features and recurrence of clinical rebounds after
each course of suppressive treatment. This 9-year-old girl, in her first attack of rheu-
matic fever, had polyarthritis, fever, positive acute phase reactants, and significant
apical systolic and mid-diastolic murmurs, without cardiomegaly. With high dosage of
prednisone, all these abnormalities disappeared promptly. The cessation of prednisone,
one week later, was followed by fever and later by a new basal diastolic murmur. The
latter persisted despite aspirin therapy. The fever whch reappeared when aspirin was
stopped subsided when prednisone was resumed and returned when prednisone was
stopped. It then subsided spontaneously but the basal diastolic murmur has persisted.
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followed by adverse effects, and the observation has served as background
for subsequent experimental studies of rebound phenomena.7
Sequelae of clinical rebounds
Figures 2 and 3 give illustrative examples of the detailed course of events
in the clinical rebounds of two patients. A summary of the clinical rebound
sequences in each of the 64 patients in this survey is given in Figures 4 to 6.
The 100 post-therapeutic clinical rebounds of these 64 patients have been
analyzed in these figures according to their clinical features and the asso-
ciated use of suppressive therapy. The results are described below:
1. Patients with no valvular involvement (Fig. 4)
In 18 patients who originally had no valvular involvement, the clinical
rebounds produced fever, tachycardia, or joint symptoms, but no evidence of
carditis. Thus, recurrent rheumatic activity in the same attack did not bring
valvular involvement to patients who were initially free of it, and the results
are consistent with preceding data which indicate that this group of patients
usually remains free of heart disease even in a completely new attack of
rheumatic fever.' Of the clinical rebounds in this group, 11 were untreated
and all subsided spontaneously without any additional effects. Of the pri-
mary clinical rebounds, 7 were treated with suppressive agents, and in 5,
when the treatment was stopped, there was a subsequent clinical rebound,
without carditis. The secondary rebounds were then left untreated and
subsided spontaneously.
2. Patients zwith valvular involvement, nithout significant cardiomegaly
(Fig. 5)
The first clinical rebound brought evidence of new carditis to 8 of the 28
patients with clinical rebounds who initially had valvular involvement with-
out significant cardiomegaly. In each case, the carditis was manifested by a
diastolic murmur which was not previously present. Of these 8 patients, 4
were untreated and the other manifestations of the rebound subsided spon-
taneously; in 3, the new murmur disappeared before the end of the convales-
cent period.* The other 4 "carditic" rebounds were treated and 3 had a
subsequent clinical rebound, (1 with carditis, 2 without) after therapy was
stopped again. Two of the secondary rebounds were then left untreated and
* The one patient in whom the new murmur persisted was found to be free of it when
re-examined two years later.
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FIG. 3. Recurrent episodes of fever and erythema marginatum after repeated courses
of steroid treatment. In this 7-year-old boy's first attack of rheumatic fever, the
arthralgias disappeared before hospitalization. On admission he had the apical systolic
murmur of mitral regurgitation, slight enlargement of the left atrium, fever, and
erythema marginatum. The murmur and slight cardiomegaly persisted thereafter. The
fever and erythema marginatum subsided after one week of prednisone, returned when
it was stopped, subsided when it was resumed, returned when it was again stopped and
then subsided and reappeared once more following a third course of prednisone therapy.
They then subsided spontaneously.
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all of their clinical -features subsided spontaneously. The other was treated,
and cessation of treatment was followed by a tertiary rebound.
The other 20 primary clinical rebounds in this group consisted of fever
alone in 7, and of joint features and/or nonfebrile tachycardia in 13. Of the
8 noncardiac primary rebounds which were left untreated, all but 2 subsided
without recurrence. One of these patients had a spontaneous secondary clin-
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FIG. 4. Sequence and nature of events before and after clinical rebounds in 18 patients
wuith no initial valvular involvement. This figure and Figs. 5 and 6 follow a similar
arrangement. The blocks at the left represent a group of patients, with cardiac status
as indicated, who had a clinical rebound when their first course of anti-rheumatic
treatment was stopped. The arrows pointing to the right indicate the subsequent events
in each patient, with or without additional clinical rebounds, until rheumatic activity
ended. The numbers refer to the number of patients in each category. The patients who
were "treated" received steroids and/or salicylates. The shading of the blocks indicates
the most severe features of the rebounds, as shown in the associated legend of each
figure.- For further details, see text.
ical rebound manifested again by joint symptoms, while the other (who pre-
viously had had only fever) developed a spontaneous secondary rebound,
manifested by a new diastolic murmur. In this patient, the second rebound
was treated, and the new murmur and other manifestations then disappeared.
In the first patient, all abnormalities subsided without further treatment.
Suppressive treatment was given to 12 of the clinical rebounds in whom
there was no evidence of provoked carditis. The cessation of treatment was
followed by another rebound in 7 patients and of these secondary rebounds,
2 were treated, both of whom had a third rebound wvhen treatment was
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stopped. The tertiary rebounds were then left untreated and subsided spon-
taneously. Of the 5 secondary rebounds which were not treated, 4 subsided
spontaneously; arthritis reappeared as a tertiary rebound in 1 patient who
had had persistent chorea in the interval between rebounds.
It should be noted that the appearance of new murmurs was the only
major feature of carditis in the clinical rebounds of this group of patients.
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FIG. 5. Sequence and nature of events before and after clinical rebounds in 28 patients
who initially had valvular involvement but no significant cardiac enlargement. (See
further description of Fig. 4.)
Congestive failure or cardiac enlargement did not occur. Of the 10 murmurs
which appeared at the time of the rebounds, all but 2 disappeared after sev-
eral months, and the disappearance seemed to be unrelated to the presence
or absence of additional therapy during the rebounds.
3. Patients zwith valular involvement, with significant cardiomegaly
(Fig. 6)
Of the 18 clinical rebounds in this group, 5 had new carditis, manifested
by congestive failure in 2, by new diastolic murmurs in another 2, and by
pericarditis in the last. All of the carditic rebounds and 5 noncarditic
rebounds were treated; all 10 of the treated rebounds were followed by a
secondary clinical rebound when the treatment was discontinued. In the
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group who had carditis with the first rebound, the second rebound renewed
the congestive failure in the two patients who had it previously, and brought
pericarditis to a patient whose previous newly acquired murmur had dis-
appeared in the interval between the first and second rebound. Two others
developed only fever. Both of the febrile rebounds were treated and both
were followed by another rebound; the tertiary rebounds were untreated
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FIG. 6. Sequence and nature of events before and after clinical rebounds in 18
patients zeith valvular involvement and significant cardiac enlargement. (See further
description of Fig. 4.)
and subsided spontaneously. One of the congestive failure rebounds was
treated and was followed by another rebound, manifested by arthritis. The
other congestive failure rebound was untreated and subsided spontaneously.
A group of 8 clinical rebounds were left untreated. These rebounds
manifested by fever alone in 7 and by arthritis in 1. All but one subsided
without recurrence. In one patient, a second rebound occurred spontane-
ously and included increased cardiomegaly with congestive failure. Its
treatment at this time was followed by a tertiary rebound which was treated,
followed by another rebound. This patient had unusually prolonged rheu-
matic activity, of the type described in a separate survey of "chronic"
rheumatic fever.'
Figures 4 to 6 illustrate that clinical rebounds did not bring carditis to
those patients who did not have it previously; in the patients with previous
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carditis, they brought significant cardiac enlargement or congestive failure
only to those who had had it previously. A major point of these figures is
better demonstrated in Table 1 which shows the occurrence of subsequent
rebounds in relation to the type of each clinical rebound and its manage-
ment. In patients whose rebound consisted only of fever or febrile tachy-
cardia, additional rebounds occurred in 11 of the 12 patients whose previous
TABLE 1. OCCURRENCE OF SUBSEQUENT CLINICAL REBOUNDS IN RELATION
To TYPES OF CLINICAL REBOUND AND THEIR MANAGEMENT
Classification of clinical
rebounds according to most
severe manifestations
Fever or febrile tachycardia
Joint symptoms or signs, and/or
nonfebrile tachycardia, and/or
erythema marginatum
New diastolic murmurs
Pericarditis and/or congestive
heart failure
Total
No anti-inflammatory
Anti-inflammatory treatment treatment given to
given to clinical rebound clinical rebound
Number fol- Number fol-
lowed by lowed by
Number subsequent Number subsequent
of epi- clinical of epi- clinical
sodes rebounds sodes rebounds
12 11 27 2
17 11
7
7
5
6
43 33
24 2
5 0
1 0
57 4
rebound was treated, but only in 2 of the 27 whose previous rebounds were
left untreated. In patients whose rebound consisted only of joint abnormal-
ities, nonfebrile tachycardia, or erythema marginatum, with or without
fever, subsequent rebounds occurred in 11 of the 17 patients whose earlier
rebounds were treated, but only in 2 of the 24 who were untreated. In
patients with new diastolic murmurs, subsequent rebounds appeared in 5 of
the 7 who were treated, and in none of 5 who were not treated. When the
rebound included more severe cardiac manifestations, additional rebounds
occurred in 6 of the 7 patients who were treated but did not occur in the
1 patient who was left untreated.
These results demonstrate that most clinical rebounds subside without
additional therapy and without additional complications. Two possible
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exceptions may be noted: (i) patients with severe carditis during a primary
rebound are usually treated immediately and the untreated sequelae of this
complication are therefore uncertain; (ii) patients with "chronic" rheu-
matic activity, discussed separately,' show a truly polycyclic course in
which relapses often occur without relationship to preceding therapy. The
presence of "chronic" rheumatic activity may be suspected when a clinical
TABLE 2. OCCURRENCE OF SUBSEQUENT CLINICAL REBOUNDS IN RELATION TO
TYPES OF CLINICAL REBOUND AND AGENT USED FOR THEIR TREATMENT
Classification of clinical Agent used to treat rebounds* rebounds according to
most severe manifestation Salicylates Steroids Combined therapy
Fever or febrile tachycardia 2/3 9/9 0/0
Joint symptoms or signs
and/or nonfebrile tachycardia 5/11 6/6 0/0
and/or erythema marginatum
New diastolic murmurs,
pericarditis, or congestive 4/5 4/5 3/4
heart failure
Total 11/19 19/20 3/4
* In each instance, the denominator represents the number of patients whose clinical
rebound was treated with this agent; the numerator represents the number in whom
another clinical rebound occurred when treatment was reduced or discontinued.
rebound occurs without a temporal relation to preceding therapy or when it
fails to resolve spontaneously.
Agent of treatment for clinical rebounds
Table 2 shows the types of clinical rebounds which were treated, the anti-
inflammatory agents used, and the occurrence of subsequent rebounds when
these agents were reduced or discontinued. In the rebounds which did not
produce new carditis, subsequent rebounds occurred in all of the 15 patients
treated with steroids and in only 7 of the 14 treated with salicylates. It is
not likely that this could occur by chance alone (X2 = 7.3, p <0.01).
In the group who had carditis with their clinical rebounds, none of the
three therapeutic regimens was able to prevent or affect the recurrence of
subsequent clinical rebounds. They re-appeared after 4 of the 5 episodes
treatedwith salicylates, 4 of the 5 treated with steroids, and 3 of the 4 which
received combined therapy.
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Duration ofrheumatic "rebound" activity
The duration of the new rheumatic inflammation which occurred with
clinical rebounds is best measured in those which were not treated. Table 3
shows how long the acute clinical and laboratory abnormalities persisted in
the 31 primary clinical rebounds which did not receive further therapy. (It
should be noted that none of the rebounds in this untreated group included
congestive failure. The most severe cardiac features were new diastolic
murmurs or nonfebrile tachycardia.) In contrast to the relatively short
duration of the clinical features in these rebounds, the associated laboratory
abnormalities lasted for a month or more in a majority of patients. The
clinical abnormalities subsided for 21 patients in less than 1 week and for 8
patients in less than 2 weeks. In the latter group, the manifestations which
lasted longer thana week were fever, tachycardia, or arthralgias. In 2 of the
patients with previous valvular involvement, nonfebrile tachycardia per-
sisted for 2 to 3 weeks and, in each case, a spontaneous clinical rebound
occurred later, and the patients showed "chronic" rheumatic activity.
These results suggest that most clinical rebounds, with the exception of
those involving congestive failure, will spontaneously subside within two
weeks even though their laboratory abnormalities may last much longer. If
the clinical features persist for more than 2 weeks, the presence of "chronic"
rheumatic activity is likely.
Prevention of clinical rebounds
The previous study' demonstrated that clinical rebounds did not occur in
patients who were either untreated or who received a long course (more
than 8 weeks) of salicylates alone. These two therapeutic approaches are
generally used, however, only in patients with little or no cardiac involve-
ment. Many physicians will continue to use steroids for patients with severe
carditis, and with few exceptions" will maintain suppressive therapy for at
least 8 weeks. Previous work'''l' has shown that steroid therapy, given
alone for this length of time, is frequently followed by clinical rebounds
regardless of the methods used to reduce and stop the medication.
A number of therapeutic designs have attempted to prevent these post-
steroid rebounds. Most designs have involved treatment with a combination
of steroids and salicylates in which steroids are started, salicylates are added
at some point, and salicylates are continued after the steroids are stopped.
The differences in various programs depend upon the time at which the
salicylates are added. One plan8 starts the two drugs simultaneously,
another adds salicylate after a week of steroids,' a third begins salicylates
when the sedimentation rate has reached normal values on steroids.'
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The present data and those acquired in the previous' study may be used
to compare the effectiveness of these regimens. Table 4 shows the results of
two types ofcombined treatment programs. In both programs, the salicylates
were continued after steroids were stopped. In the "simultaneous" regimen,
the two drugs were started at the same time. In this group, steroids were
maintained for an average of 30 days and salicylate for 60 days. Of the 25
TABLE 5. INCIDENCE OF PRIMARY CLINICAL REBOUNDS IN RELATION TO
INITIAL CLINICAL STATUS: COMPARISON OF LONG COURSES (EIGHT
WEEKS OR MORE) OF STEROID TREATMENT AND COMBINED THERAPY
Steroid treatment alone Combined therapy*
No. of No. of
clin- clin-
No. of ical re- Percent- No. of ical re- Percent-
Initial clinical status patients bounds age patients bounds age
No valvular involvement 4 2 50%o 17 2 12%
Valvular involvement
without significant 15 9 60% 17 1 6%
cardiac enlargement
Valvular involvement
with significant 11 7 64% 12 4 33%
cardiac enlargement
Total 30 18 60% 46 7 15%
* The numbers used here represent the sum of results obtained in "simultaneous" and
"overlap" combined therapy regimens, as cited in Table 4.
patients, 8 had a laboratory rebound and 5 had a clinical rebound, mani-
fested in 3 by joint manifestations and in 2 by fever; none had new cardiac
involvement. The "overlap" regimen was tested as described above, and in
this program salicylates were started only when the reduction of steroids
began. For these patients, the length of steroid tapering, and thus of the
"overlap" period, averaged two weeks. The average duration of steroid
treatment in this group was 50 days, and salicylates were maintained for an
additional 16 days after steroids were stopped. Of the 21 patients who
received this type of therapy, 13 had laboratory rebounds. Clinical rebounds
occurred only in 2 patients, both of whom had marked cardiac enlargement
and who later demonstrated persistent "chronic" activity.
292
Volume 33, February 1961Rebound in acute rheumnatic fever SPAGNUOLO, FEINSTEIN
These results suggest that "overlap" therapy is as good as "simultaneous"
combined therapy in preventing clinical rebounds. The data also suggest
that overlap therapy may even be superior, particularly in patients with
slight or no cardiac involvement, but the numbers are not large enough for
statistical significance.
The therapy in both of these combined treatment regimens was maintained
for at least 8 weeks and their assembled results are compared in Table 5
against the data obtained previously' when steroids were used alone for this
length of time. In each of the three cardiac categories, the percentage of
clinical rebounds was lower after combined therapy than after a similar
duration of steroids alone. In the total results this reduction is statistically
significant (X2 = 14.5, p <0.01). It should be noted that the data for
"combined therapy" in the present tables differ somewhat from those pre-
sented earlier.6 The difference arises because the previous data represented
total results obtained with a variety of "combined" therapy programs while
the present data are restricted to the results of two specifically designed
programs.
It would seem that when planning a long course of suppressive therapy,
especially if steroids are to be used, the incidence of subsequent clinical
rebounds will be reduced by adding salicylates to the program, either ini-
tially or when the reduction of steroids begins, and by maintaining salicylates
alone for several weeks after steroids have been stopped.
DISCUSSION
The management and prevention of post-therapeutic clinical rebounds in
acute rheumatic fever has been the subject of numerous, and often conflict-
ing, recommendations. Some of the problems arise, as noted previously,
from the use of different criteria for definition of a rebound, from the lack of
differentiation between rebounds which included clinical abnormalities and
rebounds whose abnormalities were only in laboratory tests, and from
the failure of most published reports to classify the preceding clinical fea-
tures and to correlate them with the manifestations of the rebound. The
present investigations have shown that the rebound comprises a wide spec-
trum of laboratory and clinical signs ranging from a slight, transient eleva-
tion of the sedimentation rate in a patient with no cardiac involvement to
severe clinical manifestations with new and life-threatening cardiac damage
in patients with extensive valvular disease and marked cardiac enlargement.
Obviously the prevention, prognosis, and management of rebounds requires
a consideration of the severity of the rheumatic attack and of the severity of
the manifestations of the rebounds.
293YALE JOURNAL OF BIOLOGY AND MEDICINE
Prevention of rebounds
For patients without valvular involvement during the acute attack, it has
been shown that clinical rebounds can be prevented by withholding anti-
inflammatory therapy, by giving "overlap" combined therapy or by using
salicylates alone for more than 8 weeks. Since the rebounds in this group
are so benign, the use of long-duration salicylate therapy does not seem
warranted, and a short course may be attempted although a rebound may
follow it.
For patients with valvular involvement, many physicians are reluctant to
withhold anti-inflammatory therapy and usually want to maintain it for at
least 8weeks. When treatment is given for this length of time, rebounds are
rare after salicylates alone but occur frequently after steroids. Physicians
who feel that steroids are preferable to salicylates for the routine treatment
of this group of patients should add salicylates to the regimen in order to
minimize the post-steroid rebounds. "Overlap" combined therapy is as
effective as "simultaneous" combined therapy and offers two minor advan-
tages: (i) the salicylate portion can be appended flexibly, according to the
clinical course, at the time when the steroids have totally suppressed the
rheumatic activity and a graded progressive reduction in their dosage begins
and (ii) salicylate toxicity may be less likely to occur when the drug is used
for a shorter period.
Management of rebounds
For the management of rebounds, the available suggestions range from
those which urge that almost all rebounds be treated immediately"" to
those which recommend resumption of treatment only when the clinical fea-
tures are severe and threatening"" and, finally, to those which propose an
observation period to allow spontaneous resolution; treatment is then
resumed if the rebound fails to subside in an appropriate period of time.""
The permitted length of time varies from 24 hours to 3 weeks.
The present and previous' results indicate that a laboratory rebound is a
minor, self-limited event which will not affect the patient's clinical status,
which does not need further treatment, and which may even be made worse
by further treatment. Additional suppressive therapy will also perform no
useful service for those laboratory rebounds which recur spontaneously or
which do not subside in several weeks, since this treatment will only pro-
long the period of invalidism and since many of the laboratory rebounds
represent benign elevations in sedimentation rate which may persist for
months or years' without altering the patient's clinical condition.
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The management of clinical rebounds needs more individualized atten-
tion. Therapy for the rebound has never been known to eliminate any path-
ological features which existed before the rebound and can be expected only
to remove those which were brought by the rebound. The present data
demonstrate that many of the clinical features of rebounds will subside spon-
taneously, like their laboratory counterparts, and that additional anti-
inflammatory treatment is often followed by repeated secondary or even
tertiary rebounds. If the hypothesis is correct that many clinical rebounds
are due to the appearance of previously suppressed rheumatic inflammation,
it would seem reasonable to allow the inflammation to be dispersed without
suppression when its immediate effects are not life-threatening.
a) Patients with no valvular involvement initially
These patients are not likely to develop future heart disease' and their
clinical rebounds quickly subside spontaneously, do not recur, and do not
produce cardiac damage. Suppressive therapy for these rebounds will often
be followed by additional rebounds and an unnecessary prolongation of the
total duration of rheumatic activity.
b) Patienits with valvular involvement but without significant cardiac
enlargement
In this group of patients, the clinical rebounds may include new cardiac
manifestations; these consisted, in the present survey, only of new diastolic
murmurs without any more severe events. The noncardiac features-fever,
arthritis or arthralgia-almost always subsided spontaneously. Additional
treatment for them conferred no benefits and carried the hazard of subse-
quent rebounds. Thus, the main decision regarding the management of
clinical rebounds in this group has to do with the therapy for a newly
appeared murmur. In the present survey, there were 12 such murmurs in
the rebound period, and all but 10 vanished by the end of convalescence,
whether or not they had been treated. The high incidence with which these
"rebound" murmurs disappear, irrespective of treatment, suggests that they
do not necessarily indicate new "valvulitis" and that they may be due to
temporary alterations, to fever or tachycardia, and hence hemodynamic flow
through an already damaged valve. Suppressive therapy for these physical
factors may conceivably minimize further damage. If treatment is used,
salicylates would be preferable to steroids because they are less likely to be
followed by subsequent rebounds.
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c) Patients with significant initial cardiac enlargentent*
This group ofpatients was the only one in which clinical rebounds brought
severe or life-threatening cardiac features: pericarditis, increasing cardio-
megaly, or congestive heart failure. For these complications, the resumption
of anti-inflammatory therapy seems mandatory even though its cessation
will be followed by another rebound. The hope is that the subsequent
rebounds will be milder, and that the rheumatic inflammation will ultimately
consume itself without further cardiac damage. None of the suppressive
agents seems to be superior for this purpose in this group.
SUMMARY
A rebound in acute rheumatic fever was defined as the reappearance of
rheumatic activity after it had originally disappeared under or without sup-
pressive treatment and in the absence of an intercurrent streptococcal infec-
tion. A laboratory rebound, manifested by abnormalities only in acute
phase reactants of the blood, occurred frequently, sometimes recurred after
its initial cessation, had no clinical effects, and always subsided spon-
taneously.
Clinical rebounds, manifested by clinical as well as laboratory abnormali-
ties, appeared in 64 of 415 consecutive admissions of children and adoles-
cents with acute rheumatic fever. A total of 100 clinical rebounds occurred.
Their severity and possible prevention were directly dependent upon the
original manifestations of the rheumatic attack. The results of their manage-
ment and prognosis depended upon the severity of the initial attack and the
features of the individual rebounds.
In patients who did not have valvular involvement initially, the clinical
rebounds did not bring cardiac manifestations. In patients with valvular
involvement but without significant cardiac enlargement, the rebounds, at
their worst, brought only new murmurs but no more severe cardiac effects.
In both these groups, the manifestations of the rebounds almost always sub-
sided spontaneously within two weeks. When treated with suppressive
agents, the rebounds were often followed by additional rebounds when the
agents were discontinued. A subsequent rebound after anti-inflammatory
treatment of a previous rebound was less likely after salicylates than after
steroids. In both these clinical groups, the rebounds could be prevented by
* The decision that the heart is enlarged is a subtle matter. Many "slightly enlarged"
hearts can be "cured" by use of an appropriately wide range of normal limits or by the
realization that the child's or adolescent's cardiac silhouette may normally change
considerably with different phases of the cardiac or respiratory cycle.
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not using anti-inflammatory agents for the initial attack or by treating the
initial attack with salicylates alone for more than 8 weeks. In patients of
these two groups who were initially treated with steroids, the incidence and
severity of rebounds could be markedly reduced or prevented by adding
salicylates at the time of inception or reduction of steroid treatment and by
continuing salicylates for several weeks after steroids were stopped.
In a third group of patients, who initially had significant cardiac enlarge-
ment, the clinical rebounds could bring pericarditis, increased cardiomegaly,
or congestive failure, in addition to other noncardiac features. When con-
fined to noncardiac features, these rebounds also usually subsided spon-
taneously and frequently recurred if treated. The severe cardiac features of
primary rebounds were all treated with suppressive agents, whose cessation
was always followed by secondary clinical rebounds. No specific thera-
peutic approach to the primary rebound seemed to reduce the occurrence of
secondary rebounds in this group. The use of specific kinds of combined
steroid-salicylate therapy for the initial attack in these patients could reduce
but not completely prevent the incidence of post-therapeutic primary clinical
rebounds.
"Chronic" rheumatic activity, of unusually prolonged duration, appeared
in a small percentage of patients and was characterized by clinical rebounds
which did not subside spontaneously and which occurred without a direct
temporal relationship to preceding suppressive treatment.
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